Clinical Trials
21 trialsCAR-T Followed by Bispecific Antibodies
Abramson Cancer Center at Penn Medicine
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
ModeX Therapeutics, An OPKO Health Company
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
LTZ Therapeutics, Inc.
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Virginia Commonwealth University
DALY II Japan
Miltenyi Biomedicine GmbH
HO170DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
ODIN
University Health Network, Toronto
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
The First Affiliated Hospital of Soochow University
Q702 for the Treatment of Patients With Hematologic Malignancies
Mayo Clinic
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
Memorial Sloan Kettering Cancer Center
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Florida International University
C402
Shanghai Exuma Biotechnology Ltd.
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
The First Affiliated Hospital with Nanjing Medical University
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
The First Affiliated Hospital of Xiamen University
AZA Combined With RCHOP in P53-mutated DLBCL.
The First Affiliated Hospital of Xiamen University
HOVON161
University Medical Center Groningen
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
Zhejiang Provincial People's Hospital
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
Australasian Leukaemia and Lymphoma Group